the macrophage, with its potential to exert a broad range of proinfl ammatory and/or antiinfl ammatory activities, is the conductor.
Macrophage activation can be divided into two modes, according to a useful classifi cation scheme that has emerged in recent years ( 1, 2 ) . Classical macrophage activation (M1), which is essentially proinfl ammatory, can be induced by interferon (IFN)-␥ and triggers the release of interleukin (IL)-12, the induction of nitric oxide (NO) synthase 2 (NOS2), and the up-regulation of major histocompatibility complex (MHC) class II expression. M1 macrophages are thought to play a key role in the phagocytic killing of microbes and the initiation of humoral immunity. Alternative macrophage activation (M2), by contrast, results in an antiinfl ammatory phenotype. Alternative activation is driven by IL-4 and IL-13 and yields macrophages that express lower levels of MHC class II and produce less IL-12 and NO. Decreased NO production results from a STAT-6 -dependent, arginase-mediated depletion of arginine, the substrate for the NO-generating enzyme NOS2 ( 3 ). M2 macrophages produce higher levels of antiinfl ammatory factors such as IL-10, and are thought to play a primary role in the resolution of infl ammation and the coordination of tissue repair after the acute infl ammatory reaction.
The ubiquitous family of heterodimeric NF-B transcriptional regulators coordinates responses to exogenous stress that aff ect cell activation, proliferation, and survival ( 4, 5 ) . Consequently, NF-B is a pivotal player in infl ammatory processes during immune responses and cancer ( 6, 7 ) . However, the involvement of NF-B signaling pathways in the development of M1 versus M2 macrophage activation is poorly understood. Several years ago, NF-B was shown to be active in macrophages not only during the induction of infl ammation, wherein it primarily drives proinfl ammatory gene activation, but also during the resolution of infl ammation, wherein it preferentially drives antiinfl ammatory gene activation and the induction of macrophage apoptosis ( 8 ) .
At baseline, NF-B is kept inactive through the action of I B. When extracellular signals (e.g., pathogen-associated molecular patterns) engage specifi c integral membrane receptors (e.g., Tolllike receptors [TLRs]), IKK enzymes phosphorylate I B leading to its ubiquitination and eventual degradation, thus freeing NF-B to enter the nucleus and activate gene expression ( 9 ) . IKK ␤ , a subunit of the IKK complex, is a wellrecognized activator of NF-B and consequent target for NF-B inhibition. Two studies in this issue, by Hagemann et al. lator in limiting macrophage activation and promoting the resolution of infl ammation during certain infections. Previous work has shown that the other IKK catalytic subunit, IKK ␣ , suppresses NF-B activation by accelerating the turnover of NF-B subunits RelA and c-Rel and thus their removal from proinfl ammatory gene promoters. Consistently, inactivation of IKK ␣ in mice led to enhanced infl ammation and bacterial clearance ( 19 ) . One obvious implication of these studies is that our immune capacity for bacterial eradication is perhaps not as good as it could be due to counterbalancing mechanisms that limit tissue injury and resolve infl ammation. A more sinister implication is that certain microbial pathogens, in a fashion analogous to tumor cells, have evolved mechanisms to manipulate NF-B signaling pathways and thus skew macrophage activation toward a more immunosuppressive phenotype, which facilitates their survival within the host.
Therapeutic manipulation of macrophages through IKK ␤ inhibition?
Developing eff ective therapies against cancer poses one of the greatest challenges to human medicine. Besides the nonspecifi city of many cytotoxic anticancer regimens, the abnormal and unstable genome of cancer cells may promote the development of intrinsic and acquired resistance mechanisms that render the tumor refractory to chemotherapy ( 20 ) . Similarly, the capacity of microorganisms to evolve drug resistance, which has been amply demonstrated since the introduction of antibiotics seven decades ago, compromises treatment of infections worldwide, a fact illustrated by the current epidemics of multidrug-resistant Staphylococcus aureus and Mycobacterium tuberculosis ( 21 ) . These realities beg the question of whether the tumor cell or the pathogen is ultimately sustainable as the principle target of therapy. The new studies by Hagemann et al. and Fong et al. defi ne a novel role for IKK ␤ in promoting M2 macrophage activation, away from the M1 phenotype that is optimal for clearance of bacteria and infections. This group used Cre/ lox gene targeting to delete IKK ␤ in either myeloid lineage cells (macrophages and neutrophils) or airway epithelial cells. The resulting mice had surprisingly diff erent responses to an infectious challenge depending on the cell type that lacked IKK ␤ . In a bacterial pneumonia model, clearance of group B Streptococcus (GBS) and neutrophil recruitment to the site of infection were decreased in mice with IKK ␤ -defi cient airway epithelia as compared with littermate controls. In marked contrast, neutrophil recruitment and clearance of GBS were enhanced in mice with IKK ␤ -defi cient myeloid cells, rendering these mice more resistant to pneumonia and lethal systemic GBS infection. The IKK ␤ -null macrophages had increased expression of IL-12, NOS2, and MHC class II and decreased expression of IL-10 and arginase 1, consistent with a proinfl ammatory M1 phenotype. Biochemical analyses suggested that IKK ␤ normally inhibits STAT-1 activation, which is required for responsiveness to IFN-␥ and thus the M1 mode of macrophage activation ( Fig. 1 ).
The precise mechanisms underlying the enhanced immunity seen in mice lacking IKK ␤ in myeloid cells remain unclear, as statistically signifi cant differences in direct killing of GBS by macrophages or neutrophils were not observed in vitro ( 11 ) . NO is not eff ectively bactericidal against GBS, nor is it required for GBS killing by macrophages ( 17 ); however, inhibition of NO production by aminoguanidine increased mortality in a GBS sepsis model ( 18 ) . It is thus likely that NO plays an indirect, proinfl ammatory role in stimulating the enhanced antibacterial defense demonstrated in the study by Fong et al. The authors ' fi ndings are not specifi c to GBS, as macrophages from mice with IKK ␤ -defi cient myeloid cells also resisted the characteristic switch to an M2 phenotype in response to Cryptococcus neoformans infection. The mice were consequently better able to recruit T cells and resolve the infection.
These observations suggest that the outcome of IKK ␤ activation during infection is tissue specifi c, and reveal a previously unknown role for this reguovarian cancer cells promotes macrophage diff erentiation toward the M2 profi le ( 13 ) . Signals from the TAMs in turn promote tumor cell migration, invasiveness, and metastasis ( 14 ) . The dependency of cancers on this alliance with M2-type macrophages is exemplifi ed by experimental mammary tumor models. In these models, increased macrophage infi ltration promotes the development of a supportive vasculature and malignant conversion of the tumor ( 15 ), whereas reducing macrophage infi ltration by blocking chemokine receptors inhibits tumor growth ( 16 ) .
The study by Hagemann et al. ( 10 ) dissects the relationship between NF-B signaling and the immunosuppressive M2 phenotype of TAMs. Using bioluminescent tumor imaging, the authors assessed how selective inhibition of IKK ␤ (and hence NF-B) in macrophages aff ects cancer progression in vivo. Macrophages (bone marrow derived or isolated from an established tumor site) transfected with a dominant-negative IKK ␤ construct decreased tumor burden when transferred into tumor-bearing mice. This protection was associated with an M2-to-M1 switch in the profi le of the cells and increased STAT-1 activation, which is critical for the production of IL-12 and NO. Some of the antitumor activity of IKK ␤ -defi cient TAMs might be explained by increased NOS2 expression. However, IL-12 -mediated recruitment of natural killer (NK) cells into the tumor was found to be critical for tumor regression, as blocking IL-12 in the mice that received IKK ␤ -defi cient macrophages reduced NK recruitment and restored the rate of tumor growth to that seen in control mice. This study is the fi rst to identify NF-B signaling as a central mechanism in maintaining the immunosuppressive phenotype of TAMs.
Tissue-specifi c roles for IKK ␤ during the infl ammatory response to acute infection
The contributions of IKK ␤ /NF-B to the classical versus alternative modes of macrophage activation are further explored by Fong et al. ( 11 ) in the context of resistance to bacterial and fungal impair the antibacterial program mediated by epithelial cells. TLR-mediated recognition of pathogen associate molecular patterns leads to NF-B -dependent activation of proinfl ammatory genes, and this response is essential for defense against infectious organisms. Yet, IKK ␤ also has important antiinfl ammatory roles because targeted deletion of IKK ␤ in myeloid cells, or its prolonged pharmacologic blockade, enhances susceptibility of mice to endotoxin-mediated shock by releasing NF-B -mediated inhibition of IL-1 ␤ production ( 25 ). Moreover, rare inherited immunodeficiencies associated with aberrant NF-B signaling have been described, but to date, mutations have been found only in the regulatory subunit IKK ␥ /NEMO, mouse model of colitis-associated cancer, for example, deletion of IKK ␤ in either colonic epithelial cells or in lamina propria macrophages led to a striking decline in tumor load ( 23 ) . And whereas deletion of IKK ␤ in liver cells alone increased sensitivity to chemically induced hepatocellular carcinoma (HCC), simultaneous deletion of IKK ␤ in both hepatocytes and infi ltrating macrophages dramatically reduced the size and number of HCC-induced tumors ( 24 ) .
The results presented by Fong et al. suggest that pharmacologic inhibition of IKK ␤ might have unpredictable eff ects in the context of infection. This approach may make macrophages better killers by directing them toward an M1 phenotype, but it might simultaneously tumors. Thus, IKK ␤ inhibition could represent a novel way to " re-educate " tumor-or infection-associated macrophages and thus promote their ability to eradicate abnormal cells proliferating within us. Evidence and intuition suggest that such a therapeutic approach holds more promise in the realm of cancer than infectious diseases.
A fi rst consideration is the inability to make small molecule IKK ␤ inhibitors that are tissue specifi c. This may be less of a concern for cancer intervention because IKK ␤ /NF-B activation is detectable both in neoplastic cells and in TAMs, and appears to underlie numerous synergistic processes that promote cancer development, progression, vascularization, and metastasis ( 7, 22 ) . In a lation under hypoxic conditions, and helps to explain the strong activation of HIF-1 ␣ by lipopolysaccharide and other bacterial stimuli even at normal oxygen levels. It is interesting to speculate that alterations in the expression of HIF-1 ␣ target genes may contribute to the changes in macrophage polarization that resulted from IKK ␤ deletion, as reported by the two studies in this issue.
The insertion of HIF-1 ␣ into the mix has important implications for IKK ␤ -based therapeutic concepts. HIF-1 ␣ has already been validated as a potential new target for anticancer therapy, as animals with reduced HIF-1 ␣ expression show decreased tumor growth, vascularization, and metastasis, whereas HIF-1 ␣ overexpression has the opposite eff ect ( 34 ) . The promoter of the geneencoding vascular endothelial growth factor (VEGF) contains hypoxia-responsive elements and NF-B -binding sites ( 35 ) , and thus IKK ␤ inhibition may have a dual eff ect by depleting the VEGF required for tumor angiogenesis and increasing the tumoricidal capabilities of TAMs. However, blocking IKK ␤ (and thus HIF-1 ␣ ) may also compromise the bactericidal capacity of phagocytic cells, in particular neutrophils, which provide the fi rst line of immune defense at necrotic or hypoxic foci of infection. Because of the many complexities involved, we should probably not hold our collective breath in anticipation of broadly applicable IKK ␤ -based antiinfective therapeutics. the inhibitory protein IkB ␣ , or a TIR signaling pathway component upstream of IKK, IRAK-4 kinase ( 26 ) .
A new fi nding that must be considered alongside the data showing a role for IKK ␤ in determining the M1 versus M2 phenotype of activated macrophages is the recent observation by Rius et al. ( 27 ) , published in Nature , that IKK ␤ /NF-B activation is linked to the hypoxic response and its master regulator, hypoxiainducible factor 1 ␣ (HIF-1 ␣ ) . HIF-1 ␣ controls the evolutionarily ancient stress response to hypoxia, including activation of genes involved in energy generation (glycolysis), angiogenesis, and erythropoeisis ( 28 ) . HIF-1 ␣ was generally assumed to be regulated primarily at the posttranscriptional level through oxygenand iron-dependent prolyl hydroxlases that target the transcription factor for ubiquitination and proteasomal degradation. In their study, Rius et al. generated an IFN-inducible IKK ␤ F/F /Mx1Cre mouse to delete IKK ␤ in all IFN-responsive cells ( 27 ) . Using this approach, IKK ␤ /NF-B was shown to be a critical transcriptional activator of HIF-1 ␣ in response to hypoxia and hypoxia mimetics in cultured macrophages and in the liver and brain of intact mice.
These results provide insight into an emerging role of HIF-1 ␣ as a regulator of the innate immune response and in the proinfl ammatory function of phagocytic cells such as macrophages and neutrophils ( 29 ) . Mice with a myeloid-specifi c deletion of HIF-1 ␣ had a diminished infl ammatory response to a variety of challenges, including topical chemical irritants, collagen-mediated arthritis, and endotoxininduced sepsis ( 30, 31 ) . The ability of macrophages and neutrophils from these mice to kill bacteria was impaired both in vitro and in vivo ( 30, 32 ) . Additionally, genetic or pharmacologic augmentation of HIF-1 ␣ levels enhanced macrophage bactericidal activity ( 32, 33 ) . HIF-1 ␣ thus appears to control a switch in phagocyte activity from an " off " state in the oxygen-rich circulation to an activated state in oxygen-poor environments, such as tissue foci of infection. The study by Rius et al. demonstrates that transcriptional activation of HIF-1 ␣ by the IKK ␤ /NF-B pathway is required for HIF-1 ␣ accumu-
